In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on OncoSec Medical (ONCS), with a price target of $5. The company’s shares opened today at $0.92, close to its 52-week low of $0.68.
McCarthy observed:
“OncoSec presented new positive data for TAVO (DNA-based IL-12) in metastatic melanoma at the Melanoma Bridge 2018 meeting.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.7% and a 35.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on OncoSec Medical is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.32 and a one-year low of $0.68. Currently, OncoSec Medical has an average volume of 1.87M.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.
Read More on ONCS:
